KR101965983B1 - Antibiotic composition containing panaxynol or panaxydol - Google Patents

Abstract

According to the present invention, a fraction enriched with panaxynol or panaxydol has an excellent antibacterial effect against an anaerobic microorganism compared to an extract derived from red ginseng. According to the present invention, a method for manufacturing a fraction enriched with panaxynol or panaxydol comprises: 1) a step of extracting red ginseng with ethanol; 2) a step of obtaining a column fraction; and 3) a step of fractionating the column fraction with heavy pressure chromatography.

Description

[0001] The present invention relates to an antibiotic composition containing panaxynol or panaxydol,

The present invention relates to an antimicrobial composition comprising a process for preparing a fraction enriched with paracinol or pancuronic acid derived from red ginseng, and a fraction enriched with paracyninol or paracrystalline, wherein the antimicrobial composition of the present invention is characterized by comprising an anaerobic microorganism Lt; RTI ID = 0.0 > antimicrobial < / RTI >

In general, direct or indirect damages caused by pathogenic microorganisms cause economic, environmental and medical problems. Many problems in society as a result of corruption in the process of food distribution in the food industry, harmful and environmental pollution caused by excessive use of chemical antibiotics in agricultural products, and the appearance of antibiotic-resistant strains due to misuse of antibiotics .

As an example of antibiotic resistant strains caused by misuse of antibiotics, highly resistant strains of Staphylococcus aureus, known as the treatment of Staphylococcus aureus, the most common causal agent of human infection, have been reported and the so-called super-bacteria proliferation potential is increasing. This was the first case of Vancomycin-resistant Enterococcus in Europe in 1988 after the problem of methicillin-resistant Staphylococcus aureus treated by vancomycin in the 1970s. In late 1990, it was reported in Japan, the United States, France and Korea The development of Staphylococcus aureus resistant to vancomycin has shown the seriousness of the antibiotic resistance problem and the development of new antibiotics is urgently required.

In addition, most antibiotics currently in use are manufactured through chemical synthesis, which is costly and has many limitations such as causing side effects. Therefore, in recent years, studies for separating new antimicrobial substances from natural products have been actively conducted.

On the other hand, the physiological activity of ginseng is due to saponin, polysaccharides and peptides, and many studies have been conducted centering on ginsenoside. Thus, the central nervous system control, memory, improvement of learning efficacy and antistress action, As the various pharmacological actions such as proliferation and transfer inhibition action, antioxidative action, antidiabetic action, liver function improvement, radiation protection action and thrombogenesis inhibition are scientifically proved, the demand for medicines and functional supplements .

Among the ingredients of Panax ginseng, anticancer, antioxidant and anti-diabetic effects are known. In addition, paracystol is also used as an inhibitor of hyperlipemia (Patent Document 1). In the case of using pancake stone or pancake stones or pancake stones as raw materials, standard products made of pancycinolol had difficulty in processing and distribution due to oxidation due to deterioration. Further, it has not been disclosed yet that the antimicrobial effect against paracchinol or paracystol is particularly antimicrobial against anaerobic microorganisms.

Among the microorganisms, it is difficult to store the products because of the degeneration caused by the contamination caused by anaerobic microorganisms such as food, cosmetics, medicines and other products. Therefore, it is necessary to develop a substance showing antimicrobial effect against anaerobic microorganisms.

Korean Patent Publication No. 1944-0023474

A problem to be solved by the present invention is to determine whether a fraction derived from a natural product can be used for antibacterial purposes in order to solve the problem that a resistant strain occurs when the compound is used for antibacterial use or that the stability is lowered due to oxidation of the compound itself , And to develop a substance having high antimicrobial effect and high stability against oxidation.

In order to solve the above-mentioned problems, one aspect of the present invention provides a method for producing red ginseng, comprising: 1) extracting red ginseng with ethanol; 2) fractionating the extract obtained in the step 1) into a column to obtain a column fraction; And 3) fractionating the column fractions obtained in the step 2) by medium pressure liquid chromatography (MPLC). The present invention also provides a method for preparing the paracinisol or pancycloid-enriched fraction.

In another aspect of the present invention, there is provided an antimicrobial composition for an anaerobic microorganism comprising the paraxinol or the paracystisol-enriched fraction prepared by the above method as an active ingredient.

The paracycinol-enriched fraction of the present invention has higher antimicrobial effect than paracicinol single compound and has excellent stability against oxidation, so that it can be used for food, cosmetics, and pharmaceutical products for antimicrobial use.

The paracystol-enriched fractions of the present invention have higher antimicrobial activity than the single compound of panclosendol and are excellent in stability against oxidation, and thus can be used for food, cosmetics, and pharmaceuticals for antimicrobial use.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows the peak of the panaxynol or panaxidol-enriched fraction; RT Second main peak detected at around 40 minutes: Panaxisolin enhanced fraction, RT First main peak detected at around 35 minutes: Fractionally enriched fractions.

Hereinafter, the present invention will be described in detail.

One aspect of the present invention provides a process for preparing a panaxcinol or panadisolone enriched fraction comprising the steps of:

1) extracting red ginseng with ethanol;

2) fractionating the extract obtained in the step 1) into a column to obtain a column fraction; And

3) fractionating the column fractions obtained in step 2) by medium pressure liquid chromatography (MPLC).

The column used in the production of the purified fraction in the step 2) may be a filler such as silica gel, activated alumina, synthetic polymer, magnesium silicate, activated carbon, cellulose, ion exchange resin, etc., and aromatic synthetic resin is used as a filler That is, the column may be an aromatic type synthetic adsorbent column, and more preferably, but not exclusively, Diaion HP-20 synthetic adsorbent is used as a filler. The separation using the column can be carried out once to several times until the fraction of the desired purity is purified, and concentration and recrystallization can be carried out if necessary.

In the preparation of the purified fraction in the step 2), the desorption solvent may be a lower alcohol, preferably ethanol. When ethanol is used, ethanol or an aqueous solution of ethanol may be used. The aqueous ethanol solution may be an aqueous solution of ethanol in an amount of 30 to 100% (v / v), preferably 50 to 100% (v / v) Aqueous solution, more preferably 70% or more and less than 100% (v / v) of aqueous ethanol solution, but is not limited thereto. When the concentration of the aqueous ethanol solution used as the desorption solvent is less than the lower limit value, there is a problem in that the antimicrobial effect of the obtained fraction is lowered. In the step 2), when ethanol as the desorption solvent is added during the production of the purified fraction, For example, pressurized and flowed.

The chromatography may be performed by a column chromatography method, and may be carried out one to five times in consideration of yield and purity. The column chromatography method may preferably be one or more kinds selected from the group consisting of a low pressure liquid chromatography method, a medium pressure liquid chromatography method and a high performance liquid chromatography (HPLC) method, more preferably a medium pressure Liquid chromatography.

In step 3), water or an organic solvent may be used as a developing solvent when MLPC fraction of the column fraction is fractionated. The organic solvent may be an alcohol having 1 to 5 carbon atoms, hexane, dichloromethane, methylene chloride, chloroform, ethyl acetate, ethyl ether or a mixture thereof, preferably a mixture of ethanol and water or a mixture of methanol and water And more preferably a mixture of methanol and water. Methanol: water may be 50:50 to 100: 0, and fractionation can be performed by sequentially expanding while giving a concentration gradient to the MLPC fraction.

The MPLC fractionation step may be to selectively recover at least one peak portion detected at a UV absorbance of 240 nm to 280 nm using a mixed solvent of methanol: water = 80 to 100: 0 as a developing solvent, A mixture solvent of methanol: water = 90 to 100: 0 is used as a developing solvent, and a peak detected at a UV absorbance of 250 nm to 260 nm is selected and recovered. More preferably, the solvent is methanol: water = 100 : 0 and using a solvent of methanol: water = 100: 0 as a developing solvent and at a UV absorbance of 254 nm as a developing solvent, and more preferably by selecting a peak to be detected at a UV absorbance of 250 nm to 260 nm, But the present invention is not limited thereto. The methanol content is obtained by adjusting the polarity of the solvent to obtain a high purity purification target material at a high yield considering the yield and characteristics of the purification target material. The content of methanol differs depending on the object to be purified, and in the case of the final product of the purification in step 3), that is, the fraction enriched with panaxynol or panclosol, it is preferable that the methanol is recovered when the methanol is 100%.

The separation of the panaxynol or pancreatobacterium-enriched fractions may vary according to the retention time (RT) in the MPLC fractionation step. Two main peaks appearing at RT 32-43 min can be separated to obtain panaxycinol or paclitaxone fortified fractions. Preferably, the panaxycinol-enriched fraction can be obtained by separating the main peak appearing between 39 minutes and 43 minutes from RT, and more preferably, separating the main peak appearing within about 40 minutes from RT. In addition, preferably, the fraction enriched with pancytoskyl can be obtained by separating the main peak appearing between RT 33 minutes and 37 minutes, more preferably, separating the main peak appearing within about 35 minutes. Is characterized by the separation using column and the subsequent separation using MPLC to obtain a high content of panaxynol and pannicolite, and the separation step using the column and the separation step using the MPLC Solvent and separation conditions are important. Especially, the concentration of the developing solvent and RT in the separation step using MPLC are most important. The fractions containing panaxynol or panaxylolide obtained by this method have superiority in containing the active ingredient at an appropriate level as compared with the simple red ginseng extract and the stability against the synthetic pure product is secured. In the present invention, conditions for separating paraxinol or panaxidol, which are superior in terms of efficacy and stability, have been established.

The method for preparing the column fraction of red ginseng ethanol extract according to the present invention as described in Production Example 1-4 of the present invention is a method for recovering only non-polar (hydrophobic) substances from the red ginseng ethanol extract. The column fractions prepared by this method can enhance the antimicrobial effect as compared with the ethanol extract of red ginseng. However, since the non-polar substances contained in the ethanol extract of red ginseng do not exhibit the antimicrobial effect, the content (concentration) of the active substance is constant Resulting in a variation in the antimicrobial effect for each production lot. The deviation of the antimicrobial effect of the column fractions has become a problem in terms of consistency of efficacy since it is essential that a uniform level of efficacy is secured for medical products. The present invention solves the problem of variation in the antimicrobial effect, and when the MPLC fraction is subjected to the fractionation as in Production Example 1-5 of the present invention, the efficacy is enhanced not only by enhancing the efficacy of the effective ingredient showing antibacterial effect, . For example, the MPLC fraction of Production Example 1-5 showed uniformity of the antibacterial effect for each production lot and showed little effect variation.

In another aspect of the present invention, there is provided a paracinisol or a panax lidol enhanced fraction prepared by the above method.

The paracchinol-enriched fraction may contain 900,000 to 3,000 ppm, more preferably 850,000 to 6,000 ppm, of paracincinol based on the total weight of the paracinisol-enriched fraction, and more preferably, But it is not limited thereto. When the panaxcinol is contained below the lower limit value, the antimicrobial effect may not be exhibited. When the panaxynol is included in an amount exceeding the upper limit value, the content of panaxynol is excessively increased, so that the oxidation stability is significantly reduced .

In one embodiment of the present invention, it was confirmed that the 'paracchinol-enriched fraction' containing at least about 3000 ppm of paraxinol produced by the method of the present invention exhibited an antibacterial effect against the anaerobic microorganism.

The fraction enriched with the paracrystalline may include 500,000 to 3,000 ppm, more preferably 300,000 to 6,000 ppm, based on the total weight of the fraction enriched with the paracrystalline fraction, and more preferably, But it is not limited thereto. The antimicrobial effect may not be exhibited when the parenthesized stone is contained below the lower limit value, and when the parenthesized stone is contained in excess of the upper limit value, the content of the parenthesized stone is excessively increased, so that the oxidation stability is significantly reduced .

In one embodiment of the present invention, it was confirmed that the "panniculiolite-enriched fraction" containing at least about 3000 ppm of the pancytocyst produced by the method of the present invention exhibited an antibacterial effect against the anaerobic microorganism.

In the fractions of the present invention, the antimicrobial effect initially increased as the concentration of pancassinol or pancuronic acid increased, but in case of panaxcinol exceeding 900,000 ppm and in case of pancuritic acid exceeding 500,000 ppm, And the stability was poor. This phenomenon is presumed to be due to the fact that the components which impart structural stability of the active ingredient in the natural extract are removed during the purification process, and that the stability of the natural extract is inferior due to the common characteristics of the active ingredients derived from the natural products as well as the pancreaticolor and the parasitic stones. Therefore, the fractions of the present invention are superior in antimicrobial effect to those of simple red ginseng extract, column fraction, paracchinol, or paracystol synthesized products, and are more effective than paradoxinol or paradoxil, The effective ingredient such as stone is stably maintained, which is advantageous in terms of processing, storage and distribution. If the antimicrobial effect is higher than that of the paracchinol or pseudoepitaximone synthetic product, it is judged to be an effect of synergy with other antimicrobial effect components not included in the synthetic product.

In another aspect of the present invention, there is provided an antimicrobial composition for an anaerobic microorganism comprising the paraxinol or the paracystisol-enriched fraction prepared by the above method as an active ingredient.

The antimicrobial composition for the anaerobic microorganism of the present invention may be in the form of a pharmaceutical composition or a cosmetic composition, but is not limited thereto.

The anaerobic microorganisms may be selected from the group consisting of Propionibacterium, Streptococcus, Actinomyces, Clostridium, Helicobacter, Fusobacterium, Prevotella spp., And Porphyromonas spp., Among others. Preferably at least one of the genus Propionibacterium and the genus Streptococcus and more preferably at least one of Propionibacterium acnes and Streptococcus mutans But may include, but is not limited to, bacteria that cause cavities and periodontal disease in the oral cavity anaerobic environment, or bacteria that can cause diseases in the stomach.

The paracinisol or pancocystol-enriched fraction of the present invention has an antibacterial effect against the genus Helicobacter, thereby reducing gastrointestinal diseases including gastric cancer caused by the bacterium species contained in the genus. Helicobacter pylori can be homogeneous selected from the group consisting of Helicobacter pylori , Helicobacter heilmannii , Helicobacter felis and Helicobacter mustelae .

The paraxinol or pancreatic acid-enriched fractions of the present invention can inhibit cavities, periodontal diseases or gingivitis by having an antibacterial effect on the Streptococcus spp., The Pseudomonas spp., The Pseudomonas spp. And the Porphyromonas spp. . As Streptococcus species, there are a group consisting of Streptococcus mutans , Streptococcus sanguis , Streptococcus sanguinis , and Streptococcus salivarius subsp. Thermophils. , But is not limited thereto. The Peptide bacterium can be at least one of Fusobacterium nucleatum and Fusobacterium periodonticum . The Enterobacteriaceae may be at least one of Prevotella intermedia and Prevotella loescheii . The genus Porphyromonas may be Porphyromonas gingivalis .

The animal to be infected with the anaerobic microorganism may be a mammal such as a human, a pig, a cattle, or a goat; Fish such as carp and goldfish; And poultry such as pheasants, chickens, ducks, and turkeys.

The paraxinol or pancuronic acid-enriched fractions of the present invention have antimicrobial activity against acne bacteria, and thus can be used for a cosmetic composition for improving acne and a pharmaceutical composition for preventing or treating acne. In addition, since it has an antimicrobial effect on the caries bacteria, it can be used in a pharmaceutical composition for antibacterial or oral composition which can prevent or treat dental caries caused by caries bacteria. In addition, it can be used in foods and medicines to control contamination by anaerobic microorganisms during storage.

In one embodiment of the present invention, the antipyretic effect was excellent when treated with Propionibacterium acnes and Streptococcus mutans in which the paracinisol fraction or panadischlore fraction fractioned by MPLC was treated.

In another embodiment of the present invention, the MPCL-enriched paracchinol-enriched fraction was stored at 45 < [deg.] ≫ C in harsh conditions, and the content of paracinol survived relative to the initial paracinol content was determined. Compared with that, the panaxycinol-enriched fraction was found to retain paclitaxel content over 90% of the initial content even after storage under harsh conditions.

In another embodiment of the present invention, the MPLC fraction-enriched fractions were stored at 45 ° C in a harsh condition, and then the content of the remaining pancuronic acid was compared with that of the initial pancreatic acid. As a result, Compared with that, the pannicosteroid-enriched fractions were found to retain pannocyte content over 80% of the initial content even after storage in harsh conditions.

The paraxinol or panclosilo-enriched fractions of the present invention may be contained in the cosmetic composition in an amount of 0.01 to 30 wt%, preferably 0.01 to 20 wt%, more preferably 0.01 to 10 wt% , And even more preferably from 0.01 to 5% by weight. When the content is less than 0.01% by weight, the effect of the panaxynol or pancyclovir-fortified fraction may be insignificant. When the content is more than 30% by weight, the pancycinol or pancyclovir- The effect may be relatively low.

The cosmetic composition may be prepared in liquid or solid form using bases, adjuvants and additives commonly used in the cosmetics field. Liquid or solid cosmetics may include, for example, but not limited to, lotions, creams, lotions, bath salts, and the like.

The base, adjuvant and additives commonly used in the cosmetics field are not particularly limited, and examples thereof include water, alcohol, propylene glycol, stearic acid, glycerol, cetyl alcohol, liquid paraffin and the like.

The cosmetic composition may contain the components commonly used in cosmetic compositions as well as the panaxcinol or pancydicolite-enriched fractions of the present invention, such as antioxidants, stabilizers, solubilizers, vitamins, pigments, Such as conventional adjuvants, and carriers.

The cosmetic composition may be prepared in any form conventionally produced in the art and may be in the form of, for example, a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, oil, powder foundation, emulsion A foundation, a wax foundation, a spray, and the like, but the present invention is not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.

When the formulation of the cosmetic composition is a paste, a cream or a gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide .

When the formulation of the cosmetic composition is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of spray, a mixture of chlorofluorohydrocarbons, Propane / butane or dimethyl ether.

When the formulation of the cosmetic composition is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethylcarbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan.

When the formulation of the cosmetic composition is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

The cosmetic composition may be used alone or in combination, or may be used in combination with other cosmetic compositions other than the present invention. The cosmetic composition according to the present invention may be used according to a conventional method of use, and may be used in a number of times depending on the skin condition or taste of the user.

When the cosmetic composition is a soap, a surfactant-containing cleansing agent or a surfactant-free cleansing agent, it may be applied to the skin and then wiped off or washed off with water. The surfactant-containing cleansing formulation is a cleansing foam, a cleansing water, a cleansing towel, and a cleansing pack. The surfactant-free cleansing formulation may be a cleansing cream, , Cleansing lotion, cleansing water and cleansing gel, but is not limited thereto.

The antimicrobial pharmaceutical composition of the present invention further comprises a pharmaceutically acceptable carrier, excipient or diluent.

The pharmaceutically acceptable carrier, excipient or diluent which can be used in the present invention is not particularly limited so long as the effect of the present invention is not impaired. For example, a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, Flavoring agents, fragrances, preservatives, and the like.

Representative examples of pharmaceutically acceptable carriers, excipients or diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia rubber, alginate, calcium phosphate, calcium carbonate, calcium Methylcellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil, injectable Ester, witepsol, macrogol, tween 61, cacao paper, and laurie paper.

The antimicrobial pharmaceutical composition of the present invention may be in a form selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and injections.

The method of preparing the pharmaceutical composition may be performed according to a conventional method known in the art, and is not particularly limited.

The antimicrobial pharmaceutical composition of the present invention may be administered orally or parenterally. The dose may be appropriately selected depending on the age, sex, weight, condition, disease severity, drug form, route of administration, and duration of the subject to be administered , Generally about 5 to 500 mg / kg, preferably about 100 to 250 mg / kg, may be administered one to three times a day.

It will be apparent to those skilled in the art that the method of formulation, dosage, administration route, constituents, etc. of the pharmaceutical composition for antibacterial use of the present invention can be appropriately selected from conventional techniques known in the art.

The antimicrobial pharmaceutical composition of the present invention can be used for prevention and treatment of dental caries.

The antimicrobial pharmaceutical composition of the present invention may be used in combination with a pharmacologically active ingredient, or a pharmaceutical composition containing other effective ingredient, in addition to a fraction enriched with panaxcinol or pancreatic acid as an active ingredient.

Another aspect of the present invention relates to an antimicrobial quasi-drug.

In one embodiment, the antimicrobial quasi-drug of the present invention may be an oral composition.

Examples of oral compositions may be selected from the group consisting of toothpastes (pastes, ointments, foams), mouthwashes, mouthwashes, softeners and chewing gums, but are not limited thereto.

It will be apparent to those skilled in the art that the method of formulation, capacity, method of use, constituents, etc. of the quasi-drug for antimicrobial use of the present invention can be appropriately selected from conventional techniques known in the art.

In one embodiment, the anti-inflammatory quasi-drug of the present invention may further comprise a pharmaceutically acceptable carrier, excipient or diluent, the details of which are as described above for the pharmaceutical composition.

The anti-plague quasi-drug of the present invention can be used for prevention or treatment of dental caries.

The paracinisol or pancocystol-enriched fraction of the present invention may be contained in the oral composition in an amount of 0.01 to 30% by weight, preferably 0.01 to 20% by weight, more preferably 0.01 to 10% by weight, , And even more preferably from 0.01 to 5% by weight. When the content is less than 0.01% by weight, the effect of the panaxynol or pancyclovir-fortified fraction may be insignificant. When the content is more than 30% by weight, the pancycinol or pancyclovir- The effect may be relatively low.

Oral compositions are typically formulated with ingredients used in toothpastes. For example, an abrasive, a wetting agent, a viscosity adjusting agent, a sweetener, a preservative, a foaming agent, a fluoride agent, a dental calculus agent, a solvent, purified water and the like. Specifically, polishing agents such as precipitated silica, silica gel, calcium carbonate, hydrated alumina, sodium pyrophosphate, and calcium dihydrogen phosphate; Wetting agents such as sorbitol, glycerin, polyethylene glycol, polypropylene glycol; Surfactants such as sodium lauryl sulfate, sodium laureth sarcosinate, dodecylbenzenesulfonate, binders such as carboxymethylcellulose, carrageenan, and polyacrylates; Sweeteners such as saccharin, lactose, maltose, xylitol, aspartame, stevioside; Fluorine compounds such as sodium fluoride and sodium fluorophosphate; Antifouling agents such as methyl parahydroxybenzoate, benzoic acid, sodium benzoate, and salicylic acid; Spices; Pigment; pH adjusters and the like may be used alone or in combination of two or more.

Hereinafter, the present invention will be described in detail with reference to examples and comparative examples.

However, the following examples and comparative examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

≪ Preparation Example 1 > Production of MPLC fractions of red ginseng extract or red ginseng extract

<1-1> Preparation of red ginseng water extract

1.5kg of purified water was added to 1kg of red ginseng, and the mixture was extracted three times at 70 ° C for 8 hours. The mixture was centrifuged at low temperature and concentrated under reduced pressure to obtain 50g or more of a red ginseng water extract concentrate having a moisture content of 40%. After the solvent was completely evaporated, purified water was added to the concentrate, frozen at -70 ° C, placed in a freeze dryer for 72 hours, and then dried to obtain a solid.

<1-2> Preparation of ethanol extract of red ginseng

70% (v / v) ethanol was added to 1 kg of red ginseng in 5.5 times and extracted three times at 70 ° C for 8 hours. The extract was extracted with 50 g or more of a red ginseng alcohol extract concentrate having a moisture content of 40% by using a reduced pressure concentrator. After the solvent was completely evaporated, purified water was added to the concentrate, frozen at -70 ° C, placed in a freeze dryer for 72 hours, and then dried to obtain a solid.

<1-3> Preparation of butanol fraction from red ginseng ethanol extract

The lyophilized solid content of the red ginseng ethanol extract of Preparation Example 1-2 was diluted by adding 3 times of purified water, and then the same volume of water-saturated butanol was mixed. After allowing the butanol layer to completely evaporate, the solvent was completely evaporated, and then the purified water was added to the extract, and the mixture was frozen at 70 ° C., and the mixture was placed in a freeze dryer for 72 hours and dried to obtain a solid content .

<1-4> Preparation of column fractions of red ginseng ethanol extract

The lyophilized solid fraction of the red ginseng ethanol extract of Preparation Example 1-2 was diluted by adding 3 times of purified water, and 150 g of the diluted solution was passed through a column (Mitsubishi Chemical Industry) filled with 100 g of HP-20 ion exchange resin. The column was washed with purified water corresponding to 5 times of the diluted solution passed through the column, and ethanol was passed through the column to recover the fractions of the active ingredient attached to the ion exchange resin column. After the solvent of the obtained fractions was completely evaporated, purified water was added to the fractions, and the mixture was frozen at -70 DEG C, and the mixture was put into a freeze dryer and dried to obtain a solid fraction.

<1-5> Production of fractionated medium pressure liquid chromatography (MPLC) of red ginseng ethanol extract

The column fractions of Preparations 1-4 were fractionated by MPLC. The MPLC fractionation conditions are as follows.

Equipment used: CombiFlash ^® Rf 200 (Teledyne Isco, USA)

Detector: UV 254 nm

Column: YMC-Dispopack AT. ODS-25g: 40 g

Flow rate: 15 ml / min

Solvent: MeOH: DW = 50: 50 -> 100: 0

Running time: 60min

Loading amount: 1g

(See FIG. 1), and the second main peak detected at about 40 min RT and the first main peak detected at about 35 min RT are respectively selected as the peak of absorbance at the sample recovery: MeOH: DW = 100: 0 Respectively.

&Lt; 1-5-1 > Measurement of initial panaxynol content of the second main peak

Panacinol in the second main peak fraction of the MPLC fraction of the red ginseng ethanol extract of Preparation Example 1-5 was separated by HPLC and its concentration was measured. As a result, the concentration of paraxinol in the fraction separated from the second main peak was found to be 823,000 ppm, and this fraction was designated as "paracchinore enhanced fraction". The HPLC fractionation conditions are as follows.

Equipment: 1525 Binary HPLC Pump (Waters, USA)

Detector: 2998 PDA (Waters, USA)

Column: 4.6 mm ID X 25 cm, 5 μm (Discovery® C18, SPELCO, USA)

Injection volume: 10μl

Mobile phase Conditions: solvent A - Distilled Water; solvent B - Acetonitrile

Time Flow rate (ml / min) A (%) B (%) 0 1.2 50 50 5 1.2 50 50 20 1.2 25 75 25 1.2 0 100 30 1.2 0 100 32 1.2 50 50 50 1.2 50 50

&Lt; 1-5-2 > Measurement of initial pear drop content of first main peak

In the MPLC fractions of the red ginseng ethanol extract of Preparation Example 1-5, the pannicose stones in the first main peak fraction were separated by HPLC and the content thereof was measured. As a result, the pacification content in the fraction from which the first main peak was separated was found to be 178,000 ppm, and this fraction was designated as &quot; pancreatin-enriched fraction &quot;. HPLC fractionation conditions are the same as in Production Example 1-5-1.

Theorem for Production Example 1-5:

It was found that it was difficult to obtain a fraction having a specific compound content of 100% solely by MPLC separation by confirming the contents of pancaxidol and panaxynol contained in the fraction enriched in paracynchol or paracrystalline, respectively. In addition, even when pancassiolin or pancuronic acid is obtained as a high-quality concentrate in the past, stability in the presence of a single compound is lowered and the product is decomposed into another substance. Thus, it is possible to determine whether the fractions of the present invention have stability against oxidation Was confirmed in Example 1.

<Example 1> Confirmation of the stability of the MPLC fraction of Production Example 1-5

<1-1> Confirmation of stability of fortified fractions

The MPLC fraction (pancassinol-enriched fraction) of Panaxylol standards (Chromadex, CA, USA) and Preparation 1-5 was stored at 45 ° C for 2 weeks in a harsh condition, and then the stability test was carried out. The absorbance was read at 203 nm for PDA detector to determine parenchy- nocyte change, and the% area was confirmed. The results are shown in Table 2.

Initial (% area) After 2 weeks (% area) Initial residual amount Panaxinol (standard product) 98.26 78.26 79.6% The MPLC fraction (pancassinol-enriched fraction) of Preparation Example 1-5 85.16 79.49 93.4%

Experimental results show that the standard of panaxynol prepared by the synthesis is very poor in stability, whereas the panaxcinol in red ginseng extract is highly stable.

In particular, it was confirmed that the MPLC fraction (pancassinol-enriched fraction) of Production Example 1-5 maintained the stability of 90% or more even with a high content of paracchinol. Therefore, the MPLC fraction (pancassinol-enriched fraction) of Production Example 1-5 has a high initial pancysinol content and maintains a high initial percentage of the residual amount under the oxidizing condition, It was found that it is suitable for use as

<1-2> Confirmation of the stability of fractions fortified with pancuronic acid

The stability test was carried out after storage for 2 weeks at 45 ° C in the MPLC fraction (panniculiol-enriched fraction) of Preparation Example 1 (Chromadex, CA, USA) and Production Example 1-5. Table 3 shows the results of the experiment.

Initial (% area) After 2 weeks (% area) Initial residual amount Stripping stone (standard product) 54.75 36.44 66.6% The MPLC fractions of Preparation Example 1-5 (fragments enriched with pancuronic acid) 37.87 33.47 88.4%

Experimental results showed that the purity of parenchymal stones with high purity was very low while the stability of parenchymal stones in red ginseng extract was high. The initial% area of pancreatic stones is 54.75, which is lower than that of the initial% area of pancaxinol of 98.26, indicating that the pancarbitol is less stable than paracchinol. Compared with the initial value, the standard value of panaxynol standard was maintained at 79.6%, but the standard value of panaxystol standard was 66.6%, indicating that the stability was relatively low.

In particular, it was confirmed that the MPLC fraction of Preparation Example 1-5 (fraction containing pancytosyltransferase) retained more than 80% of stability even at high paclitaxel contents. Therefore, since the MPLC fraction of Production Example 1-5 (fractions enriched with pancuronic acid) was kept at a high ratio at the initial stage under the oxidizing conditions, it was effective in a small amount and thus it was found to be suitable for use in antibacterial use .

The Theory of Example 1:

It was found that the paracinisol or pancyclovir-enriched fractions of the present invention remained at 85% or more as compared with the respective standard products even at the initial conditions even under the oxidative conditions, and thus the stability effect was excellent. Particularly, in the case of pancreatin, the stability is lower than that of panaxycinol. However, in the case of the fractions enriched with pancyclovir of the present invention, the residual amount of the pancaricolic acid is more than 85% I could.

Example 2 Confirmation of Antimicrobial Effect of Panaxisolin-Enhanced Fractions

<2-1> Identification of antimicrobial effect against acne bacteria

The experimental group and the control group prepared in the above Preparation Example were dissolved in purified water at 12.5, 6.25, 3.13, and 1.56 mg / ml, and the antimicrobial activity against acne bacteria was confirmed by the paper disk method. Propionibacterium acnes (ATCC 6919) was cultured in Reinforced clostridial medium (difco, USA). Reinforced clostridial medium P. acne prepared on the plate medium was inoculated evenly with a sterile cotton swab. Clear zone, a range in which acne bacteria do not grow, was measured and the effect of each sample was compared. As the positive control group, benzo-peroxide and azelaic acid, which are used as the main components of the acne treatment agent, were treated at the same concentration in the general medicine. The experimental results are shown in Table 4.

12.5 6.25 3.13 1.56 The extract of Preparation Example 1-1
(Water extract) 0.0 0.0 0.0 0.0 The extract of Preparation Example 1-2
(Ethanol extract) 2.5 0.5 0.0 0.0 The butanol fraction of Preparation Example 1-3
(Ethanol extraction-butanol fraction) 5.0 4.5 3.0 1.0 The column fractions of Preparation Example 1-4
(Ethanol extraction-column) 4.0 1.5 1.0 0.0 The MPLC fraction of Preparation Example 1-5
(Flavor enhancing fraction) 6.0 5.5 4.5 4.0 Control 1
(Synthetic paraxinol standard) 3.0 3.0 3.0 3.0 Control group 2
(Benzo-peroxide) 7.0 6.0 5.0 3.0 Control group 3
(Azelaic acid) 0.0 0.0 0.0 0.0

As a result, the antimicrobial effect against acne bacteria was excellent when ethanol was used as compared with the case where water was used as a solvent. Among the ethanol extracts, it was found that when the ethanol extract was fractionated with butanol or subjected to column purification, the antibacterial effect was superior to that of the ethanol extract itself.

In the case of Production Example 1-5, which is a fraction of red ginseng extract containing panaxcinol as an active ingredient, obtained by fractionating the column fractions of Production Example 1-4 with MPLC, Production Examples 1-1 to 1 -4 and the anticancer effect was superior to that of control group 1, which is a standard of panaxillin, and the antibacterial effect was equivalent to that of the control 2, which is a general medicine. Through this, it can be seen that the paracchinol of Preparation Example 1-5 of the present invention It was found that the antimicrobial synergistic effect was exhibited by these components because the fractions contained other components than panaxynol.

In addition, the antimicrobial effect of the extracts or fractions of Preparations 1-1 to 1-4 during treatment at a low concentration tended to be significantly reduced, while the fraction enriched with paracchinol of Preparation 1-5 was low The antimicrobial effect was maintained at a high level.

From the above results, among the red ginseng extract, fractions containing panaxynol exhibit high antimicrobial effect even at a low concentration, and thus can be usefully used in fields requiring an antimicrobial effect.

<2-2> Identification of antimicrobial effect against cavities

To investigate the antimicrobial effect of the extracts or fractions prepared in the above Preparation Example against other microorganisms other than acne bacteria, the cavity-inducing bacteria (S. mutans) (Korea Research Institute of Bioscience and Biotechnology) were cultured in Reinforced clostridial medium (difco, USA) Respectively. The antibacterial effect was confirmed in the same manner as in the method of Example <2-1> described above. As a control group, thymol, menthol, and methyl salicylate, which are used as main ingredients for paracinol standards and oral cleaning products, were used. The experimental results are shown in Table 5.

6.25 3.13 1.56 The extract of Preparation Example 1-1
(Water extract) 0.0 0.0 0.0 The extract of Preparation Example 1-2
(Ethanol extract) 0.0 0.0 0.0 The butanol fraction of Preparation Example 1-3
(Ethanol extraction-butanol fraction) 0.0 0.0 0.0 The column fractions of Preparation Example 1-4
(Ethanol extraction-column) 0.0 0.0 0.0 The MPLC fraction of Preparation Example 1-5
(Flavor enhancing fraction) 4.0 2.5 2.0 Control 1
(Synthetic paraxinol standard) 2.0 1.5 1.0 Control group 2
(Thymol) 2.0 0.5 0.0 Control group 3
(menthol) 0.0 0.0 0.0 Control group 4
(Methyl salicylate) 0.0 0.0 0.0

As a result of confirming the antimicrobial effect, the extracts or fractions of Production Examples 1-1 to 1-4 showed no antibacterial effect against the cavities. On the other hand, the paracchinol-enriched fractions of Preparation Example 1-5 showed antimicrobial effect against cavities, and the antimicrobial effect was maintained even at a low concentration, and a standard product containing more than 98% ) Showed higher antimicrobial effect.

In Example < 2-2 &gt;, the column fractions of Preparation Example 1-4 had an antibacterial effect against acne bacteria, whereas in Example < 2-3 &gt;, the column fractions of Preparation Example 1-4 showed antibacterial effect against cavities In order to apply the antimicrobial effect to all the anaerobic microorganisms including acne bacteria and tooth decay bacteria, The fractions were found to be suitable.

From the above results, it can be seen that the paracycinol-enriched fractions of the present invention exhibit an antibacterial effect against anaerobic microorganisms such as acne bacteria and tooth decay bacteria. In the field requiring antibacterial effect against anaerobic microorganisms, Enhanced fractions can be used.

<2-3> Identification of antimicrobial effect against aerobic bacteria and fungi in addition to anaerobic bacteria

To confirm that the paraxinol-effective fraction of Production Example 1-5 of the present invention had an antibacterial effect on other microorganisms other than the anaerobic bacteria such as the above Examples <2-1> and <2-2>, E. coli ( E. E. coli (ATCC) (using Trypticase Soy Agar), P. aeruginosaaero (Korea Research Institute of Bioscience and Biotechnology) (using Trypticase Soy Agar as a medium), C. albicans (2-1), except that a culture medium corresponding to each microorganism was used as a target, and potato dextrose agar) and A. niger (Korea Research Institute of Bioscience and Biotechnology) (the medium was using potato dextrose agar) , The antibacterial effect of each microorganism was confirmed.

As a result of confirming the antibacterial effect, the antibacterial effect against E. coli, Pseudomonas aeruginosa, yeast bacteria and fungi was not exhibited even though the same sample was treated. From these results, it can be seen that the active ingredient of paraxinol of Production Example 1-5 of the present invention shows an excellent antimicrobial effect against anaerobic microorganisms such as acne bacteria or dental caries bacteria among microorganisms, but exhibits no antibacterial effect against other aerobic bacteria or fungi And it was found that, among the microorganisms, the antimicrobial effect was specifically shown only for anaerobic bacteria.

&Lt; Example 3 > Confirmation of antimicrobial effect of fractions enriched with pancuronic acid

<3-1> Identification of antimicrobial effect against acne bacteria

The test group and the control group prepared in the above Preparation Example were dissolved in purified water at 12.5 and 6.25 mg / ml, and the antimicrobial activity against acne bacteria was confirmed by the paper disk method. Propionibacterium acnes (ATCC 6919) was cultured in Reinforced clostridial medium (difco, USA). Reinforced clostridial medium P. acne prepared on the plate medium was inoculated evenly with a sterile cotton swab. Clear zone, a range in which acne bacteria do not grow, was measured and the effect of each sample was compared. As the positive control group, benzo-peroxide and azelaic acid, which are used as the main components of the acne treatment agent, were treated at the same concentration in the general medicine. Table 6 shows the results of the experiment.

12.5 6.25 The extract of Preparation Example 1-1
(Water extract) 0.0 0.0 The extract of Preparation Example 1-2
(Ethanol extract) 1.5 0.0 The butanol fraction of Preparation Example 1-3
(Ethanol extraction-butanol fraction) 2.5 2.5 The column fractions of Preparation Example 1-4
(Ethanol extraction-column) 2.0 0.5 The MPLC fraction of Preparation Example 1-5
(Fractions with enhanced penetration) 4.0 3.0 Control 1
(Synthetic parabolic stone standard product) 3.0 3.0 Control group 2
(Benzo-peroxide) 5.0 5.0 Control group 3
(Azelaic acid) 0.0 0.0

As a result, the antimicrobial effect against acne bacteria was excellent when ethanol was used as compared with the case where water was used as a solvent. Among the ethanol extracts, it was found that when the ethanol extract was fractionated with butanol or subjected to column purification, the antibacterial effect was superior to that of the ethanol extract itself.

In addition, the fractions of the red ginseng extract of Preparation Example 1-5, which was obtained by fractionating the column fractions of Production Example 1-4 with MPLC and using pancarcystol as an active ingredient, The extracts or fractions of Examples 1-4 were superior to the control group 1 of paracystinol standard, and showed the same antimicrobial effect as that of the control 2, which is a general medicine. From these results, it can be seen that the fractions of Production Example 1-5 of the present invention contain other components other than pancuritic acid, so that the antimicrobial synergistic effect is exhibited by these components.

From the above results, among the red ginseng extracts, fractions containing pannicola stones exhibit a high antimicrobial effect and thus can be usefully used in fields requiring an antimicrobial effect.

<3-2> Identification of antimicrobial effect against aerobic bacteria and fungi in addition to anaerobic bacteria

E. coli (ATCC) was used to confirm that the fractions enriched with paclitaxel of Production Example 1-5 of the present invention had an antibacterial effect on other microorganisms other than the anaerobic bacteria as in Example <3-1> (Medium is Trypticase Soy Agar), P. aeruginosaaero (Korea Biotechnology Research Institute) (medium is Trypticase Soy Agar), C. albicans (Korea Biotechnology Institute) (medium is potato dextrose agar) And the same antimicrobial test method as in Example <2-1> except that the culture medium corresponding to each microorganism was used for A. niger (Korean Biotechnology Research Institute) (the medium was using potato dextrose agar) The antimicrobial effect of each microorganism was confirmed by the method.

As a result of confirming the antibacterial effect, the antibacterial effect against E. coli, Pseudomonas aeruginosa, yeast bacteria and fungi was not exhibited even though the same sample was treated. From these results, it can be seen that the fractions enriched with paclitaxel of Production Example 1-5 of the present invention exhibit an excellent antimicrobial effect against anaerobic microorganisms such as acne bacteria among microorganisms, but exhibit no antibacterial effect against other aerobic bacteria or fungi And it was found that, among the microorganisms, the antimicrobial effect was specifically exhibited only for the anaerobic bacteria.

The Theory of Examples 1 to 3:

The paracinisol or pancyclovir-enriched fractions of Production Example 1 of the present invention exhibit a high antimicrobial effect specifically for anaerobic microorganisms and have a higher stability against oxidation compared to pure synthetic products such as panaxynol or paganosidol , It is useful as a raw material for cosmetics, household products, and pharmaceutical compositions that require an antimicrobial effect against anaerobic microorganisms instead of conventional compound antibiotics because of its excellent antimicrobial effect.

PREPARATION EXAMPLE 2 Preparation of Cosmetic Composition

<2-1> Preparation of essence

Using the MPLC fraction (pancassinol-enriched fraction) of Preparation Example 1-5, an essence was prepared according to the content (parts by weight) shown in Table 7 below.

Furtherance Content (parts by weight) Triethanolamine 0.25 Carboxyvinyl polymer 0.22 glycerin 4 Butylene glycol 2 The MPLC fraction of Preparation Example 1-5 1.5 Wax 0.5 Cetostearyl alcohol One Glyceryl monostearate One Squalene 4 Purified water Suitable amount

<2-2> Production of softening longevity

The softening longevity of the MPLC fraction of Preparation Example 1-5 (pancreatobacterium-enriched fraction) as an active ingredient was prepared as shown in Table 8 below.

Raw material Content (parts by weight) 1,3-butylene glycol 1.00 Disodium iodide 0.05 Allantoin 0.10 Dipotassium glycyrrhizate 0.05 Citric acid 0.01 Sodium citrate 0.02 Glycereth-26 1.00 Arbutin 2.00 PEG-40
Hydrogenated castor oil 1.00 ethanol 30.00 The MPLC fraction of Preparation Example 1-5 0.5 coloring agent a very small amount Flavoring agent a very small amount Purified water Balance

<2-3> Preparation of nutritional cream

The nutritional cream containing the MPLC fraction (pancassinol-enriched fraction) of Preparation Example 1-5 as an active ingredient was prepared as shown in the composition of Table 9 below.

Raw material Content (parts by weight) 1,3-butylene glycol 7.0 glycerin 1.0 D-Panthenol 0.1 Magnesium aluminum silicate 0.3 PEG-40 stearate 1.2 Stearic acid 2.0 Polysorbate 60 1.5 Chin type glyceryl stearate 2.0 Sorbitan sesquioleate 1.5 Cetearyl alcohol 3.0 Mineral oil 4.0 Squalene 3.8 The MPLC fraction of Preparation Example 1-5 1.5 vegetable oil 1.8 Dimethicone 0.4 Dipotassium glycyrrhizate a very small amount Allantoin a very small amount Sodium hyaruronate a very small amount Tocopheryl acetate Suitable amount Triethanolamine Suitable amount Flavoring agent Suitable amount Purified water Balance

<2-4> Production of Lotion

Lotions containing the MPLC fraction of Preparation Example 1-5 (pancreatoprecipitated fraction) as an active ingredient were prepared as shown in Table 10 below.

Raw material Content (parts by weight) Cetostearyl alcohol 1.6 Stearic acid 1.4 Pro-type glycerin monostearate 1.8 PEG-100 stearate 2.6 Sorbic acid sesquioleate 0.6 Squalene 4.8 Macadia oil 2 Jojoba oil 2 Tocopheryl acetate 0.4 Methylpolysiloxane 0.2 Tocopheryl acetate 0.4 1,3-butylene glycol 4 Xanthan gum 0.1 glycerin 4 d-Pandenol 0.15 The MPLC fraction of Preparation Example 1-5 1.0 Allantoin 0.1 Carbomer (2% aq. Sol) 4 Triethanolamine 0.15 ethanol 3 Purified water Suitable amount

PREPARATION EXAMPLE 3 Preparation of Pharmaceutical Compositions and Oral Compositions

<3-1> Preparation of injection

Injection preparations were prepared according to the contents (parts by weight) shown in the following Table 11 using the MPLC fraction (pancassinol-enriched fraction) of Preparation Example 1-5.

Furtherance Content (mg) The MPLC fraction of Preparation Example 1-5 100 Sodium metabisulfite 3.0 Methyl paraben 0.8 Propylparaben 0.1 Sterile sterilized water for injection Suitable amount

The above ingredients were mixed and made into a final volume of 2 ml by a conventional method, filled in an ampoule and sterilized to prepare an injection.

<3-2> Preparation of tablets

Tablets were prepared according to the contents (parts by weight) shown in Table 12 below using the MPLC fractions of Preparation Example 1-5 (pancreatobacterium-enriched fractions).

Furtherance Content (mg) The MPLC fraction of Preparation Example 1-5 200 Potato starch 100 Lactose 100 Colloidal silicic acid 16 Magnesium stearate Suitable amount

The ingredients were mixed and tableted according to a conventional tablet preparation method to prepare tablets.

&Lt; 3-3 > Preparation of capsules

Using the MPLC fraction (pancassinol-enriched fraction) of Preparation Example 1-5, capsules were prepared according to the content (parts by weight) shown in Table 13 below.

Furtherance Content (mg) The MPLC fraction of Preparation Example 1-5 100 Lactose 50 Starch 50 Talc 2 Magnesium stearate Suitable amount

The ingredients were mixed according to a conventional capsule manufacturing method and filled in gelatin capsules to prepare capsules.

<3-4> Manufacture of pills

A pellet was prepared according to the content (parts by weight) shown in the following Table 14 using the MPLC fraction of Production Example 1-5 (pancreatobacterium-enriched fraction).

Furtherance Content (mg) The MPLC fraction of Preparation Example 1-5 120 Corn starch 100 Sterile distilled water Suitable amount

The above ingredients were mixed and pelletized to spheres of appropriate size according to conventional pellet manufacturing methods to produce pellets.

<3-5> Preparation of oral composition

<3-5-1> Manufacture of Toothpaste

Using the MPLC fraction (pancassinol-enriched fraction) of Preparation Example 1-5, an essence was prepared according to the content (parts by weight) shown in Table 15 below.

Furtherance Content (parts by weight) The MPLC fraction of Preparation Example 1-5 20 glycerin 6 Sodium saccharin 0.1 Silica 7 Precipitated calcium carbonate 39 Sodium lauryl sulfate 2 menthol 0.4 peppermint oil 0.1 Purified water Balance

The above ingredients were mixed, and toothpaste was prepared according to a conventional toothpaste manufacturing method.

<3-5-2> Others

An oral composition was prepared by adding an appropriate amount of the MPLC fraction (pancassinol-enriched fraction) of Production Example 1-5 to various mouthwashes, mouthwashes, ointments or chewing gum oral care products.

Claims (18)

1) extracting red ginseng with ethanol;
2) fractionating the extract obtained in the step 1) into a column to obtain a column fraction; And
3) fractionating the column fractions obtained in step 2) by medium pressure liquid chromatography (MPLC), which method comprises the steps of:
In step 3), the column fractions were fractionated using methanol, Or a 50% (v / v) or more to less than 100% (v / v) aqueous methanol solution, and sequentially fractionally developing and fractionating the mixture to obtain a fraction enriched with paracinisol or paracystol. The method according to claim 1,
Wherein the column is a synthetic adsorbent column of aromatic type. The method according to claim 1,
Wherein the desorption solvent at the time of column fractionation is ethanol, wherein the panaxcinol or pancuricolite-enriched fraction is ethanol. delete The method according to claim 1,
The MPLC fractionation step may be carried out using methanol as a developing solvent; Or less than 80% (v / v) to less than 100% (v / v) of water and at least one peak portion detected at a UV absorbance of 240 nm to 280 nm, Or fractions thereof. The method of claim 5,
Wherein the MPLC fractionation step uses methanol as the developing solvent and selectively recovers at least one peak portion detected at 254 nm UV absorbance. The method of claim 5,
And separating two main peaks appearing at 32 to 43 minutes of retention time (RT). The method of claim 7,
Wherein the main peak appearing between 39 and 43 minutes is removed during the production of the panaxillum enhanced fraction. The method of claim 7,
And separating the main peak appearing between 33 minutes and 37 minutes at RT during preparation of the pancreatic enhancer fraction. A paracinisol or panaxylol fortified fraction prepared by the process for the preparation of the panaxcinol or paracrystalline enhanced fraction of claim 1. The method of claim 10,
Panaxisolin-enriched fraction is panaxcinol or panaxylol fortified fraction containing panaxcinol at 900,000 to 3,000 ppm based on the total weight of the panaxylolone-enriched fraction. The method of claim 10,
The fractions enriched with paracrystalline are paracchinol or paracystol fortified fractions containing 500,000 to 3,000 ppm of the paracrystalline fraction relative to the total weight of the paracrystalline fraction. 10. An antimicrobial cosmetic composition for an anaerobic microorganism comprising the paraxinol or the paracystol-enriched fractions of claim 10 as an active ingredient. A pharmaceutical composition for antimicrobial use against an anaerobic microorganism comprising the paraxinol or the paracrystalline-enhanced fraction of claim 10 as an active ingredient. 14. The method of claim 13,
The anaerobic microorganisms may be selected from the group consisting of Propionibacterium, Streptococcus, Actinomyces, Clostridium, Helicobacter, Fusobacterium, Wherein the composition is at least one selected from the group consisting of Prevotella genus, Porphyromonas genus. 15. The method of claim 14,
The anaerobic microorganisms may be selected from the group consisting of Propionibacterium, Streptococcus, Actinomyces, Clostridium, Helicobacter, Fusobacterium, Wherein the composition is at least one selected from the group consisting of Prevotella genus, Porphyromonas genus. A cosmetic composition for improving acne, comprising the paraxinol or the paracrystalline-enhanced fraction of claim 10 as an active ingredient. A pharmaceutical composition for preventing or treating acne, comprising the paraxinol or the paracrystalline enhanced fraction of claim 10 as an active ingredient.

Images